In order to identify new atypical antipsychotic drugs which are more selective for the human dopamine D4 receptor than for the human dopamine D2 (long) receptor, we tested enantiomer pairs of dopamine agonists and dopamine antagonists on the expressed proteins of these cloned receptors. The (+)-aporphines ((+)-N-propyl-norapomorphine, 11-OH-N-propyl-norapomorphine and (+)-apomorphine) bound to the dopamine D4 receptor with selectivities up to 20 times greater than to the dopamine D2 receptor, suggesting that these pharmacologically inactive enantiomers may succeed as atypical neuroleptics.